Tebao Biotech (688278.SH): ACT201 injection obtained drug clinical trial approval notice

Zhitongcaijing · 2d ago

Zhitong Finance App News, Tebao Biotech (688278.SH) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the company's application for the drug clinical trial of ACT201 injection was approved.

ACT201 injection is an innovative antisense oligonucleotide (ASO) drug with characteristics such as ① significantly increasing RNaseH-mediated antiviral activity ② moderately increasing human TLR8 (hTLR8) agonist activity ③ less off-target effect and ④ improving ASO liver and kidney distribution ratio. Its drug innovation and importance have been recognized and selected for the 2025 National Science and Technology Project for Innovative Drug Research and Development.